West Pharmaceutical Services (NYSE:WST) Updates FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 7.850-8.200 for the period, compared to the consensus EPS estimate of 7.730. The company issued revenue guidance of $3.2 billion-$3.3 billion, compared to the consensus revenue estimate of $3.2 billion.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $246.97 on Thursday. West Pharmaceutical Services has a one year low of $187.43 and a one year high of $324.33. The stock has a market capitalization of $17.77 billion, a price-to-earnings ratio of 36.59, a PEG ratio of 3.32 and a beta of 1.18. The company has a 50-day simple moving average of $262.32 and a 200-day simple moving average of $261.73. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.21. The firm had revenue of $805.00 million for the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the company posted $1.82 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, analysts predict that West Pharmaceutical Services will post 6.62 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.4%. West Pharmaceutical Services’s payout ratio is presently 13.04%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on WST shares. Evercore decreased their price target on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a report on Tuesday, February 3rd. TD Cowen initiated coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They set a “buy” rating for the company. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Finally, Morgan Stanley started coverage on shares of West Pharmaceutical Services in a report on Monday, December 1st. They set an “equal weight” rating and a $285.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Buy” and an average price target of $326.22.

Institutional Trading of West Pharmaceutical Services

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC grew its position in West Pharmaceutical Services by 16.1% during the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 224 shares during the period. Intech Investment Management LLC boosted its stake in shares of West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after acquiring an additional 1,307 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of West Pharmaceutical Services by 14.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares during the period. EverSource Wealth Advisors LLC increased its stake in West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 197 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after purchasing an additional 29,067 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.